GRAL logo

GRAIL INC

GRALNASDAQ
🏆 #1030 by market capEarnings Nov 4 · PostUS Equity
$159.76▲ $1.94 (+1.23%)
Latest quote
🔔
Track GRAL
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.2%
7d▲ 25.8%
14d▲ 18.1%
30d▲ 16.7%
ytd▲ 86.6%
1y▲ 87.9%
🏦Market Cap
$7.14B
Small Cap
📈Revenue Growth (YoY)
23.1%
Healthy
📊Gross Margin
49.7%
Healthy
💵FCF Margin
—
⚖️P/S Ratio
42.7x
Expensive
Otter Score
60
Fair

Trading Snapshot

Day Range
$156.75 – $161.45
52-Week Range
$41.50 – $166.48
Volume (shares)
12,930
Avg Volume (shares)
—
Shares Outstanding
44.7M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
$147M
Last Q Revenue
$45M
P/E Ratio
—
P/S Ratio
42.7x
EPS (TTM)
$-9.75
Dividend Yield
—
Dilution (1yr)
+27.7%
GRAL logo

GRAIL INC

GRAL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$147M▲ +17.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-42.5%▼ −31.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$534M▼ −75.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$299M▼ −48.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
40.7M▲ +27.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$152M▲ +$6M YoY
StockOtter · stockotter.space

About GRAIL INC

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Ratings

ⓘ
Consensus
Buy
17 analysts
Strong Buy4
Buy6
Hold7
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.